Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) Operating Expenses (2016 - 2025)

Haemonetics has reported Operating Expenses over the past 17 years, most recently at $135.0 million for Q4 2025.

  • Quarterly results put Operating Expenses at $135.0 million for Q4 2025, changed 0.35% from a year ago — trailing twelve months through Dec 2025 was $531.3 million (down 3.64% YoY), and the annual figure for FY2025 was $527.1 million, changed 0.09%.
  • Operating Expenses for Q4 2025 was $135.0 million at Haemonetics, down from $136.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for HAE hit a ceiling of $146.0 million in Q1 2024 and a floor of $98.0 million in Q4 2021.
  • Median Operating Expenses over the past 5 years was $121.4 million (2023), compared with a mean of $122.5 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 108.75% in 2021 and later dropped 16.61% in 2025.
  • Haemonetics' Operating Expenses stood at $98.0 million in 2021, then grew by 17.75% to $115.4 million in 2022, then grew by 14.26% to $131.9 million in 2023, then rose by 1.99% to $134.5 million in 2024, then increased by 0.35% to $135.0 million in 2025.
  • The last three reported values for Operating Expenses were $135.0 million (Q4 2025), $136.3 million (Q3 2025), and $138.4 million (Q2 2025) per Business Quant data.